deltatrials
Completed PHASE1 INTERVENTIONAL 6-arm NCT04417465

First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors

Sponsor: AbbVie

Conditions Advanced Solid Tumors Cancer
Interventions ABBV-CLS-579 PD-1 inhibitor VEGFR TKI
Updated 20 times since 2020 Last updated: Sep 24, 2025 Started: Jun 3, 2020 Primary completion: Aug 21, 2025 Completion: Aug 21, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Advanced Solid Tumors Cancer, this trial is completed. The trial is conducted by AbbVie and has accumulated 20 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Jul 2022 · 10 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Jun 2023 · 9 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Jan 2024 · 5 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Sep 2025 · 11 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 9 months · monthly snapshot

Change History

20 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Oct 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  4. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

▶ Show 15 earlier versions

  1. Jan 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

  2. Aug 2023 — Jan 2024 [monthly]

    Recruiting PHASE1

  3. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE1

  4. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE1

  5. Sep 2022 — Jun 2023 [monthly]

    Recruiting PHASE1

  6. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  7. Sep 2021 — Jul 2022 [monthly]

    Recruiting PHASE1

  8. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  9. Mar 2021 — May 2021 [monthly]

    Recruiting PHASE1

    Status: Active Not Recruiting → Recruiting

  10. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1

  11. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  12. Nov 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  13. Sep 2020 — Nov 2020 [monthly]

    Recruiting PHASE1

  14. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE1

  15. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE1

    First recorded

Jun 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
  • Calico Life Sciences LLC
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bordeaux, France , Chuo-ku, Tokyo, Japan , Fort Wayne, United States , Huntersville, United States , Kashiwa-Shi, Japan , Madrid, Spain , Málaga, Spain , New Haven, United States , Pittsburgh, United States , Ramat Gan, Israel and 5 more locations